news
-
7 October 2019Axonics® Broadens EU Commercial Footprint with Recommendation for Reimbursement in France and Supply Contract in Norway
Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing a novel implantable rechargeable sacral neuromodulation (“SNM”) system, today announced it achieved two milestones that expand its commercial reach in France and Norway. Specifically, the French Haute Autorité de Santé (“HAS”) published a positive recommendation required to gain reimbursement in France, and in Norway, a contract was awarded to supply the Axonics r-SNM® System to SNM-implanting hospitals in key cities.
The technical and clinical evaluation by HAS concluded that the therapeutic benefit of the Axonics r-SNM System for the treatment of Overactive Bladder is sufficient for registration on the Liste des Produits et Prestations Remboursables (“LPPR”). Registration is anticipated by the end of Q1 2020 following approval by the French Department of Health. HAS noted the advantages of the Axonics r-SNM System compared to InterStim®, in particular the opportunity to reduce the number of surgical procedures related to neurostimulator replacements as a result of the Axonics 15+ years long-lived implant, as well as the ability for patients to undergo full-body MRI scans without the necessity of having the device explanted. Approximately 1,000 patients receive an SNM implant in France every year.
In Norway, Axonics now has the opportunity to supply SNM products to six hospitals that were part of an evaluation process conducted by the national hospital procurement trust, Sykehusinnkjøp HF. The award states that buying decisions will be left up to implanting physicians to determine if the Axonics r-SNM System or that of the incumbent is best suited for individual patients. If a physician deems the systems to be equally suitable for a patient, it is the lifecycle costs that should determine which SNM system is selected. Approximately 500 SNM systems are envisioned to be implanted over the next four years in Norway.
Raymond W. Cohen, CEO of Axonics, commented, “While we are keenly focused on the U.S. commercial launch following our recent FDA approval, we continue parallel efforts to selectively expand our global reach, focusing on countries where reimbursement levels and the volume of implants allow our rechargeable SNM system to benefit more patients. This positive French HAS recommendation is based on an in-depth review of our technical and clinical evidence, and is testament to the technology benefits and quality of work at Axonics.”
Cohen continued, “In Norway, we look forward to supplying our product to this network of hospitals. We are confident that given a choice, patients and providers will choose and benefit from Axonics’ technology, and the healthcare system will capture the cost savings associated with our long-lived device.”
Related
Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System
Axonics® Announces Second Quarter 2019 Financial Results and Operational Update
Axonics® Announces 1-Year Top-Line Clinical Results from its ARTISAN-SNM Pivotal Study
Axonics® Announces Publication of ARTISAN Clinical Study Results in the Journal of Urology
Axonics® Announces First Quarter 2019 Financial Results and Operational Update
Axonics® Announces Fourth Quarter and Full Year 2018 Financial Results and Operational Update
Axonics® Announces Positive Top-Line Clinical Data from its ARTISAN-SNM Pivotal Study
Axonics® Announces Publication of NICE Briefing
Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Axonics® Receives Health Canada Approval for its Sacral Neuromodulation External Trial System
Axonics® Announces Closing of Initial Public Offering of Common Stock
Axonics Modulation Technologies, Inc. Announces Pricing of Initial Public Offering of Common Stock
Axonics® Receives Technology Innovation Award from Medtech Insight
Axonics® Receives CE Mark for its Sacral Neuromodulation External Trial System
Axonics® Completes Enrollment of U.S. FDA Pivotal Study for its Sacral Neuromodulation System
Axonics Announces $40 Million Financing
Axonics® Sacral Neuromodulation System Receives Marketing Approval in Australia
Axonics® Granted Seven New U.S. Patents Related to its Implantable Sacral Neuromodulation Technology
Axonics® Appoints Dr. Karen L. Noblett as Chief Medical Officer
Axonics Announces $20.5 Million Second Closing of its Series C Financing
Axonics Announces $14.5 Million First Close of Series C Financing
Axonics Granted Four U.S. Patents Related to its Implantable Sacral Neuromodulation Technology
Axonics Sacral Neuromodulation System Receives Marketing Approval from Health Canada
Axonics Granted New U.S. Patent Related to its Implantable Neuromodulation Technology
Axonics Sacral Neuromodulation System™ Receives MRI Conditional Labeling
Axonics Announces First Patients Treated in Sacral Neuromodulation Study
Axonics Granted Six U.S. Patents Related to its Implantable Neuromodulation Technology
Axonics Modulation Technologies Announces $38.5 Million Series B Financing